The collaborations will provide Illumina's customers with workflows for genomic disease characterization and spatial mapping.

Most immuno-oncology drugs work by altering the tumor microenviro | This webinar covers how recent advances in multiplex ...

Halozyme Therapeutics, Inc. ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is ...

Danaher Corp. entered into a definitive agreement to acquire Masimo in an all-cash transaction valued at approximately $9.9 billion. Madrigal Pharmaceuticals signed an exclusive global license ...

Researchers led by Xian-Yang Qin at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have developed a score ...

A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that ...

The most detailed atlas of tumour cells from the deadliest form of pancreatic cancer has been developed by an global team of researchers ...

New simulator and computational tools generate realistic ‘virtual tissues’ and map cell-to-cell ‘conversations’ from spatial transcriptomics data, potentially accelerating AI-driven discoveries in ...

Foster City, Calif. | January 27, 2026 — Signios Bio today announced the launch of a new grant program supporting innovative spatial transcriptomics research using the 10x Genomics Xenium 5K Spatial ...

Lymph nodes are key sites of adaptive immune responses, yet how immune cells coordinate their activities in space and time remains poorly understood. We combined high-resolution spatial ...

In a first, this week the U.S. Food and Drug Administration approved a brain stimulation device designed to treat depression at home. The approval of the first such device for home depression ...